Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 30 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/6/2007


1.		Phase I/II Chemoimmunotherapy with IL-2/CY, plus Tumor Infiltrating Lymphocytes in Selected Patients and alpha-Interferon in Some Patients, in Treatment of Advanced Refractory Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				any age				NCI				NCI-86-C-183E NCI-T86-0225N, T86-0225

Last Modified: 7/1/1991


2.		Phase I/II Study of IL-4 in Patients with Indolent non-Hodgkin's Lymphoma and B-Cell CLL (Summary Last Modified 07/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				16 and over				NCI				AECM-9102059 NCI-T91-0050D, T91-0050

Last Modified: 12/1/1992


3.		Phase I/II Study of TIL/IL-2 in Patients with Advanced Melanoma (Summary Last Modified 12/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				16 and over				NCI				PCI-9038 NCI-T91-0133O, T91-0133

Last Modified: 10/1/1998


4.		Phase II Study of IL-4 for Refractory non-Hodgkin's Lymphoma and Hodgkin's Disease (Summary Last Modified 10/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				adult				NCI				SWOG-9219 SWOG-9219

Last Modified: 4/25/2007


5.		Phase II Study of IL-4 in Advanced Indolent B-Cell Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				ECOG-E5Y92 E5Y92

Last Modified: 4/1/1997


6.		Phase II Randomized, Double-Blind, Placebo-Controlled Study of Two Doses of IL-4 for Unresectable Stage IIIA/B non-Small Cell Lung Cancer (Summary Last Modified 04/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				SPRI-C94-049 SCH-C94-049-01, NCI-V95-0654

Last Modified: 11/1/1995


7.		Phase II Randomized Dose-Ranging Study of IL-4 for Advanced Nonsmall Cell Lung Cancer (Summary Last Modified 11/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18				Pharmaceutical / Industry				SPRI-C94-048 SCH-C94-048-01, NCI-V95-0655

Last Modified: 6/1/1999


8.		Phase II Study of Interleukin-4 in Patients With Relapsed or Refractory B Lineage Acute Lymphoblastic Leukemia (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Over 16				NCI				SWOG-9711 S9711

Last Modified: 6/1/1999 First Published: 1/1/1998


9.		Phase II Study of Recombinant Human Interleukin-4 in Patients with Primary Myelofibrosis (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 18				Other				RPCI-DS-95-10 NCI-V97-1360

Last Modified: 6/27/2006 First Published: 8/1/2000


10.		Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				LAC-USC-10M991 NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute